BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Release Date: September 12, 2025

Expiration Date: September 12, 2026

Activity Overview

Prostate cancer continues to pose substantial clinical challenges, with increasing incidence and mortality rates in the United States. While PSMA-directed radioligand therapy (RLT) and advanced imaging technologies have transformed the diagnosis and treatment of metastatic prostate cancer, knowledge gaps persist regarding optimal use, patient selection, sequencing, and integration into multidisciplinary care. Additionally, disparities in access and implementation across care settings underscore the urgent need for clinician education.

To address these unmet needs, PER® has developed this online activity that features 4 concise modules with expert video interviews. Topics will span PSMA imaging interpretation, the science and clinical application of RLT, patient selection and toxicity management, and strategies to expand equitable access through multidisciplinary care.

Target Audience

BURST CME™ Activity 1—Imaging Matters: Decoding PSMA PET for Better Decision-Making

This activity is directed toward medical oncologists, urologists, nuclear medicine physicians, radiologists, and radiation oncologists.

BURST CME™ Activity 2—Radioligand Therapy 101: The Science Behind the Strategy

This activity is directed toward nuclear medicine physicians, medical oncologists, radiation oncologists, and urologists.

BURST CME™ Activity 3—Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

This activity is directed toward medical oncologists, radiation oncologists, and urologists.

BURST CME™ Activity 4—Working Together: Optimizing Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

This activity is directed toward medical oncologists, urologists, radiation oncologists, nuclear medicine physicians, advanced practice providers, nurses, nurse navigators, and palliative care specialists.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

BURST CME™ Activity 1—Imaging Matters: Decoding PSMA PET for Better Decision-Making

1. Determine the role of PSMA-based PET/CT scans as a key diagnostic and prognostic tool in prostate cancer
2. Discuss key elements and guidelines for PSMA PET/CT interpretation in clinical practice to support accurate clinical decision-making

BURST CME™ Activity 2—Radioligand Therapy 101: The Science Behind the Strategy

1. Discuss key elements and guidelines for PSMA PET/CT interpretation in clinical practice to support accurate clinical decision-making
2. Assess the mechanistic and clinical rationale supporting the role of PSMA-targeting radioligand therapy in the management of patients with metastatic prostate cancer

BURST CME™ Activity 3—Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

1. Integrate PSMA-directed radioligand therapy in the management of patients with mCRPC based on guideline recommendations and clinical trial evidence
2. Develop best practices for identification and management of treatment-related toxicities in patients with mCRPC being treated with PSMA-directed radioligand therapy

BURST CME™ Activity 4—Working Together: Optimizing Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

1. Identify barriers to receiving PSMA-directed radioligand therapy and strategies to expand access in the community setting.
2. Devise strategies to overcome disparities in care and ensure equitable access to novel radioligand therapies in patients with mCRPC.
3. Incorporate biomarker and imaging-based tools to guide multidisciplinary care and optimize outcomes with PSMA-targeted radioligand therapy

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.